Technology

Antibody Development

Developing monoclonal antibodies into effective medicines is complex. We enable their efficient translation into clinical applications.

PipelineChallenges

Antibody development is challenged by numerous obstacles, including detailed antibody profiling, manufacturing, and complex regulatory requirements.

AcceleratingOptimization

Bridging the gap from Discovery to Deployment

We are committed to overcoming these hurdles to accelerate development—so that antibodies can be deployed directly to patients without delay.

To achieve this, we offer targeted expertise, strategic guidance, and advanced technical capabilities across key stages of human monoclonal antibody development, ensuring a seamless transition from the laboratory bench to clinical execution.

Monoclonal Antibody Development

  1. Preclinical phase

  2. Neutralization Assays

    This includes custom-designed neutralization assays using both replication-competent and pseudotype virus systems.

  3. Pharmacokinetic Analyses

    We perform pharmacokinetic analyses in a variety of mouse models and utilize HIV-1-infected humanized mice to assess the efficacy of broadly neutralizing antibodies.

  4. Escape Mechanism Profiling

    These studies include profiling viral escape mechanisms in response to single or combination antibody therapies.

  5. Clinical Development

  6. Clinical Support & Strategic Guidance

    For clinical development, we support both observational and early-phase interventional studies, offering strategic guidance on study design, implementation, and execution.

CapabilitiesExpertise

Our team combines deep scientific expertise with strong operational know-how to advance your antibody-based solutions against infectious diseases.